Navigation Links
Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
Date:6/23/2008

MOUNTAIN VIEW, Calif., June 23 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marriott Boston Copley Place in Boston, MA. The oral platform abstract presentation, "Inhaled Loxapine, a Dopamine Antagonist, Reduces Headache Pain in Patients Having an Acute Migraine Attack", is scheduled for Friday, June 27, 2008 at 10:55 a.m. Eastern Time, and will be presented in University Hall. AZ-104 is a lower dose version of AZ-004, which is in Phase 3 clinical development for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorperazine) for the acute tre
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
2. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
3. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
4. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
7. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
10. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
11. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)...ww.christmasseals.org to learn more, make a donat...SHINGTON, Nov. 17 Milli...month, courtesy of the American Lung Association. ...ual fundraising tradition dating back to 1907 when...culosis. , , "Most Americans alive today ...
(Date:11/18/2008)...E, Va., Nov. 18 Forty-t...ed at a November national forum to consider cuttin...c health and national economy from outbreaks of da...ed today. , , Among those innovations: , ...merican kitchen table that detects highly contagio...
(Date:11/18/2008)...ed study will enroll newly diagnosed, elderly AML ...wswire/ -- Celator Pharmaceuticals today announced...omized Phase 2 clinical study of CPX-351 (Cytarabi...th newly diagnosed acute myeloid leukemia (AML). ,...eldman, MD at the Weill Medical College of Cornel...
(Date:11/13/2008)...Study Suggests Nutritional Supplements Prior to Su...re-USNewswire/ -- Identifying,malnutrition before ...dy,contouring will significantly decrease surgical...scar quality and boost patient energy levels,acco...and Reconstructive,Surgery(R), the official medica...
Breaking Medicine Technology:American Lung Association Celebrates 101st Annual Christmas Seals Campaign 242 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference 314 1Nitec Pharma AG Announces Appointments of CEO 26 CFO in Preparation for Launch of Lodotra 28R 29 311 1Nitec Pharma AG Announces Appointments of CEO 26 CFO in Preparation for Launch of Lodotra 28R 29 311 2Nitec Pharma AG Announces Appointments of CEO 26 CFO in Preparation for Launch of Lodotra 28R 29 311 3Society for General Microbiology 161st Meeting University of Edinburgh 217 1Society for General Microbiology 161st Meeting University of Edinburgh 217 2A drug sensitive traffic cop tells potassium channels to get lost 364 1A drug sensitive traffic cop tells potassium channels to get lost 364 2
...rvard Medical School ,Contributing Editor , ,... per year, breast cancer undoubtedly qualifies as ...ently, efforts to develop early detection methods ...gress. This is particularly true at the molecular...ve translated into new diagnostic tests and target...
...ibuting Editor ,Harvard Medical School ,The...two of the most important classes of fungi in clin...onment, and hospitals are no exception. Perhaps t...a ) and pulmonary hypersensitivity ( Aspergillus )...tions, but by virtue of intact physical barriers a...
Other Medicine Technology:Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy 2Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy 3New Assays to Detect Disseminated Fungal Infections 2New Assays to Detect Disseminated Fungal Infections 3
(Date:11/21/2008)... Nov. 21 Heska Corporati...ent at the New York Society of,Security Analysts,...ce on,December 2, 2008 at 1177 Avenue of the Amer... is scheduled to begin at 9:35 a.m. Eastern Time (...a live webcast and for two weeks,following the pr...
(Date:11/21/2008)...remain cautious about future antibiotic resistance...21 (HealthDay News) -- People with moderate to sev...ay be able to reduce the frequency of exacerbation...ic, a new report says. , The study, published ...ournal of Respiratory and Critical Care Medicine ,...
(Date:11/21/2008)... The University of Tex...ing of a collaborative effort to eradicate breast ...t Cancer Awareness and Research of the Americas to... the United States, and Vivian Fernandez de Torrij.... D. Anderson in the initiative are the U.S. Depar...
(Date:11/21/2008)...rs Intend To Vigorously Protect Investment And Res... 21 Dr. Stephen Joffe, ...ent to their Schedule 13D with the U.S. Securities...led a 13D disclosing ownership of 11.4% of LCA-Vis...ikPlus fixed-site laser vision correction centers ...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7
...y has selected Indian ministry of health and famil...or its "unrelenting stance on health promotion and... Welfare Anbumani Ramadoss will receive the award ...ce on Tobacco in Washington DC Friday, a ministry ...
...th African Indian Siamese twins are doing well and...nielle and Danika Lowton, born on June 21 at the A...ng their oral feeds. "They are gaining weight and...the Post newspaper quoted Wian Stander, head of th...
... live-saving stem cells, seven banks of umbilical ...st of the series will open in Gurgaon this// month...ks International, a US body, and R.J. Corporation ... will invest Rs.1 billion to build the seven repos...
...t was smuggled into the United States was found in...s over the past month. Michigan health// officials...to official reports there is no sign that the froz...rails intact, had been contaminated with the deadl...
Other Medicine News:Health News:First Cord Blood Bank in North India to be Opened in Gurgaon 2
...versatile means of sectioning fresh or fixed, anim...g blade principle which allows sectioning without ... the alteration of morphology, the destruction of ...nherent in freezing or embedding procedures are th...
...ovides a versatile means of sectioning fresh or fi... vibrating blade principle which allows sectioning...rtifacts, the alteration of morphology, the destru...effect inherent in freezing or embedding procedure...
...provides a versatile means of sectioning fresh or ... a vibrating blade principle which allows sectioni... artifacts, the alteration of morphology, the dest...s effect inherent in freezing or embedding procedu...
Instrument Cover for Vibratome.
Medicine Products: